Neurocrine Biosciences Officer Files to Sell $43k in Stock
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Neurocrine Officer Files Intent to Sell Stock
Company: NEUROCRINE BIOSCIENCES INC (NBIX) Form: 144 | Filed: 2025-11-05 Significance: Low
Insider: Gano Kyle Title: Officer, Director | Relationship: Officer, Director
Transaction (Proposed): • Type: Proposed Sale • Shares: 300 • Approx. Value: $42,591
Key Insight: An officer has filed their intention to sell a small amount of stock, valued at approximately $43k. The sale is planned under a Rule 10b5-1 trading plan adopted a year prior, indicating it was pre-scheduled.
Market Context: The transaction size is negligible, representing less than 0.001% of the company's $14.28 billion market cap. This is a routine filing with no material impact expected.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: NEUROCRINE BIOSCIENCES INC (NBIX)
Executive Summary
- Trading Significance: Low
- Key Takeaway: An officer filed a notice of proposed sale for a minor amount of stock ($42,591), representing a negligible fraction of the company's market capitalization.
- Market Impact: Neutral. The transaction is too small to have any market impact.
Company Information
| Field | Value |
|---|---|
| Company | NEUROCRINE BIOSCIENCES INC |
| Ticker Symbol | NBIX |
| CIK | 0000914475 |
| Industry | BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) |
Insider Information
| Field | Value |
|---|---|
| Name | Gano Kyle |
| CIK | 0001567160 |
| Title/Position | Officer, Director |
| Relationship | Officer, Director |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 144 |
| Transaction Date | 2025-11-04 (Approximate) |
| Transaction Code | N/A (Proposed Sale) |
| Security Type | Common Stock |
| Shares Involved | 300 |
| Price Per Share | $141.97 (Approximate) |
| Total Value | $42,591 |
| Shares Owned After | Not specified |
| Ownership Type | Not specified |
Financial Impact Assessment
Transaction Materiality
| Metric | Value |
|---|---|
| Transaction Value | $42,591 |
| % of Market Cap | 0.0003% |
| Shares Transacted | 300 |
| % of Shares Outstanding | 0.0003% |
| Post-Transaction Ownership | Not specified |
| Materiality Assessment | Low |
Impact Evaluation
- Market Cap Context: The proposed sale of $42,591 is insignificant against Neurocrine's market capitalization of $14.28 billion.
- Transaction Significance: The number of shares (300) is a tiny fraction of the 99.18 million shares outstanding. This transaction is considered routine and non-material from a market perspective.
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: A Form 144 filing for a sale of this small size, especially under a pre-arranged trading plan, is a common occurrence and does not signal any change in insider sentiment or company fundamentals.
Volume & Sentiment
- Expected Volume Impact: None. The transaction is too small to affect trading volume.
- Sentiment Indicator: Neutral. This filing carries no bullish or bearish signal.
Additional Context
Transaction Notes
- Special Circumstances: The filing notes a plan adoption date of November 1, 2024, indicating this proposed sale is pursuant to a Rule 10b5-1 trading plan. Such plans are established in advance to avoid trading on non-public information.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.